samedan logo
 
 
spacer
home > pmps > winter 2002 > improving the clinical trial supply chain by using best practice techniques
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Improving the Clinical Trial Supply Chain by Using Best Practice Techniques

What's the best way to ensure that clinical trial compounds are correctly packaged, labelled and delivered, while still maintaining tight control of costs? That's an increasingly critical question for companies in the pharmaceutical industry, where better manufacturing and supply processes can make the difference between a smooth and timely clinical trial and a costly debacle - drug makers lose up to a million US dollars in sales for each day a new drug's market launch is delayed.

As clinical studies become more complex and protracted, these supply chain issues grow even more pressing. To meet the challenge, leading pharmaceutical companies are implementing best practice processes, such as the deployment of cross-functional project teams. But many companies are still not using software tools to optimise production planning and execution.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Harald Geimer, Director of Worldwide Life Sciences and
Frank H Schulze, Principal of Worldwide Life Sciences Practice at PRTM

Harald Geimer is Director of Worldwide Life Sciences Practice at PRTM. He has over 14 years' consulting experience, primarily in supply chain management and product and process development, spanning the pharmaceutical, biotech, chemicals and medical devices industries.

Harald has led projects for companies to facilitate improvement in product development, supply chain management processes and outsourcing strategies. His consulting experience prior to joining PRTM, focused on business process re-engineering in the area of logistics, and marketing and service development in purchasing and supply management.

Harald holds a Masters Degree in Business Studies and Engineering from the Technical University in Darmstadt, Germany.

Frank H Schulze is Principal of Worldwide Life Sciences Practice at PRTM. He has 15 years of industry and consulting experience in developing business strategies and organisational concepts, sales and marketing, strategic product portfolio analysis, optimising R&D portfolios, integrating acquisitions and managing projects within the pharmaceutical, chemical, consumer and medical diagnostics industries. Prior to joining PRTM, Frank worked as General Manager of the Central and Eastern European Region for Hoechst Marion Roussel (now Aventis).

He was a Team Leader for the merger of Hoechst and Roussel in Europe and Latin America and managed the integration of Marion Merrill Dow (MMD). Frank also held senior management positions in several pharmaceutical and chemical companies. He has a PhD in Science from the Max-Planck-Institut in Gцttingen, Germany and a Masters Degree in Biology from the University of Heidelberg.


spacer
Harald Geimer
spacer
spacer
spacer
Frank H Schulze
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Thermo Fisher Scientific Adds Patterned Microchip-based Technology to Liquid Chromatography Portfolio

PHILADELPHIA – ASMS 2021 – (November 1, 2021) – Thermo Fisher Scientific, the world leader in serving science, today announced its acquisition of Belgium-based PharmaFluidics, the developer of the μPAC range of micro-chip-based chromatography column.
More info >>

White Papers

The Flexible Factory Concept: A flexible bioprocessing platform to meet the changing needs of biomanufacturing

GE Healthcare Life Sciences

For the past several years, the biopharma industry has been buffeted by dynamic market conditions that are rapidly reshaping manufacturing requirements. These factors include: • The rise of small-market pharmaceuticals that do not require the production scale of the previous “blockbuster” drug model • Increased titers and process productivity that generate more bulk-product within a much smaller manufacturing footprint • The emergence of biosimilars and continued evolution of healthcare reform, which will increasingly pressure drug pricing and require greater cost discipline • Greater competition and shorter patent protection timelines, which will further ratchet up time-to-market pressures • Tighter capital markets that will create heightened scrutiny for all new investment projects
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement